GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » EV-to-Revenue

HighTide Therapeutics (HKSE:02511) EV-to-Revenue : (As of Jun. 06, 2024)


View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, HighTide Therapeutics's enterprise value is HK$1,505.09 Mil. HighTide Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00 Mil. Therefore, HighTide Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for HighTide Therapeutics's EV-to-Revenue or its related term are showing as below:

HKSE:02511's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.83
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-06), HighTide Therapeutics's stock price is HK$4.55. HighTide Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00. Therefore, HighTide Therapeutics's PS Ratio for today is .


HighTide Therapeutics EV-to-Revenue Historical Data

The historical data trend for HighTide Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics EV-to-Revenue Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-Revenue
- - -

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue - - - - -

Competitive Comparison of HighTide Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, HighTide Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HighTide Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's EV-to-Revenue falls into.



HighTide Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

HighTide Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1505.089/0
=

HighTide Therapeutics's current Enterprise Value is HK$1,505.09 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HighTide Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HighTide Therapeutics  (HKSE:02511) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

HighTide Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=4.55/0
=

HighTide Therapeutics's share price for today is HK$4.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HighTide Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


HighTide Therapeutics (HKSE:02511) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Executives
Ma Lixiong 2101 Beneficial owner
Liu Liping 2101 Beneficial owner
Li Li 2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao 2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc. 2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p 2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited 2101 Beneficial owner
Hepalink (hong Kong) Limited 2201 Interest of corporation controlled by you
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 2501 Other
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited 2101 Beneficial owner
Lai Hoi Man 2201 Interest of corporation controlled by you
Hongtu Capital Limited 2101 Beneficial owner

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines